Novel drug delivery system based on jcv-vlp

2:

• The VLP as recited in claim 1, whereas the VLP is derived from JCV.

3:

• The VLP as recited in claim 1, whereas the drug delivery system crosses the blood-brain barrier to enter the CNS together with the drug encapsulated by the VLP.

4:

• The VLP as recited in claim 1, wherein the drug delivery system crosses the physiologically intact blood-brain barrier.

5:

• The VLP as recited in claim 1, wherein the VLP is composed of VP1 proteins of JC virus.

6:

• The VLP as recited in claim 1, wherein the VLP is prepared for intravenous administration.

7:

• The VLP as recited in claim 1, wherein the VP1 comprises an amino acid sequence which is at least 80% identical to the amino acid sequence according to SEQ ID NO:
• 1 over its entire length and/or wherein the VP2 comprises an amino acid sequence which is at least 80% identical to the amino acid sequence according to SEQ ID NO:
• 3 over its entire length.

8:

• The VLP as recited in claim 1, wherein the drug is selected from the group consisting of a cytotoxic agent, a detectable agent such as a radionuclide, a protein, a peptide and a nucleic acid, in particular selected from the group consisting of nucleic acids encoding a desired protein such as mRNA, cDNA, a plasmid or vector;
• inhibitory nucleic acids such as siRNA or miRNA;
• and nucleic acids having catalytic activity such as a ribozyme.

9:

• A pharmaceutical composition comprising the VLP as recited in claim 1, wherein at least 1%, preferably at least 15%, more preferably at least 50%, in particular preferred at least 95% of the total amount of drug substance (cargo) is fully encapsulated in the hull of the VLP.

10:

• The pharmaceutical composition as recited in claim 9, wherein the VLP are non-aggregated.